logo-loader

Kintara Therapeutics appoints Dr Mario Lacouture to its scientific advisory board for cutaneous metastatic breast cancer

Published: 09:20 03 Mar 2021 EST

Kintara Therapeutics -
The REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy.

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) has hired cancer expert Dr Mario Lacouture to its Cutaneous Metastatic Breast Cancer (CMBC)-focused scientific advisory board. 

Dr Lacouture is director of the oncodermatology program at the Memorial Sloan Kettering Cancer Center and a Professor of Dermatology at Weill Cornell Medicine in New York City. His appointment comes as the company prepares its REM-001 therapy for late-stage pivotal testing for the condition. 

READ: Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for recurrent glioblastoma multiforme

In 2012, CancerCare named him Physician of the Year for his contributions to the education of people living with cancer and he has been on Castle-Connolly and New York Magazine's list of Top Doctors (2014-2021).

"We are pleased to welcome Dr Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication," said Saiid Zarrabian, Kintara's chief executive in a statement on Wednesday.

"We look forward to working closely with Dr Lacouture, utilizing his experience as a leading expert in the treatment of CMBC to ensure REM-001's pivotal clinical trial is optimally designed and executed."

The REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy.

With clinical efficacy of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of around 1,100 patients across multiple indications, Kintara is advancing the CMBC program with the candidate to late-stage pivotal testing.

Contact the author at giles@proactiveinvestors.com

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

2 hours, 5 minutes ago